Articles On Resonance Health (ASX:RHT)

Futures suggest the ASX will open lower to cap off the working week following a mixed session on Wall Street overnight. Meanwhile, oil prices plunged, sinking to below US$70 a barrel. On home soil, here are some ASX-listed companies w...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data employment outcomes for the first time  ACCC gives the thumbs down to Telstra and TPG’s merger plans   The ASX 200 gained 1.29% today and...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Resonance Health (RHT) is contracted to provide services for two new clinical trials addressing iron-overload disordersThe company has signed contracts with two new pharmaceutical customers to provide FerriScan, Cardiac-T2, and related anal...

Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Resonance Health’s (RHT) flagship product, FerriScan, is now available for use on 3T MRI scanning machines FerriScan is internationally regarded by clinicians as the “gold standard” to measure liver iron concentration for patients with iro...

The ASX is set to open slightly lower on Monday US social media stocks tumbled on Friday, with Snap plunging by 39% Ahead this week, US Fed’s rate decision and Australia’s June quarter CPI Local shares are set to dip on Monday, with the A...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

ASX ends the week sore-arsed and red-faced Some shining glimmers of hope rise among wildly swinging small caps GUD has a ‘Guh’ moment as profit downgrade sends investors scurrying   The ASX has spent this week being led by the nose into s...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Resonance Health (RHT) signs a platform integration and partnership agreement with CARPL.ai CARPL.ai is the world’s first testing and deployment platform for medical imaging AI that connects healthcare providers to third-party AI applicati...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

The S&P/ASX200 is about seven points lower on Monday after a day of choppy trade, heavily impacted by some large cap hits, like Magellan (down about 10%) and an earlier whack for the big four banks after ANZ put out a profit warning. Bu...

Medical imaging software Resonance Health (ASX:RHT) has received the green light in the US for its LiverSmart medical device, making it eligible for recognition by the US government agencies and private insurers. Resonance received confirma...

Resonance Health (RHT) contracted by Chinese company Hangzhou Zede Pharma-Tech to provide services for a clinical study into a treatment for patients with blood disorders The company says the Hangzhou Zede Pharma-Tech study will use its Fe...

Local markets had a breather in the form of a mid-week public holiday, but things weren’t much better once trading recommenced on Thursday. After initially jumping by more than 1%, the ASX microcap Emerging Companies index reversed course w...

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for Invictus Ops, a wholly-owned subsidiary of VGI Health Technology, for its clinical study of a potential new treatment for NASH.

Medicinal cannabis stock Cann Group (ASX:CAN) has scored a regulatory milestone, after being granted a GMP licence to manufacture CBD therapeutic goods in its Southern facility in Victoria. The GMP (or Good Manufacturing Practice) license w...

ASX investors got back in the risk saddle on Wednesday, with steady gains across the large cap indexes and a 1.7% jump for the microcap Emerging Companies index. The catalyst appeared to be comments from US Fed Chair Jerome Powell overnight...

The ASX is down -0.3% today with the information technology sector taking the cake for the biggest dip at ~3%, followed by the healthcare sector at more than 1.5%. The ASX Emerging Companies Index (XEC) has flatlined. For the second day in...

ASX investors evidently shrugged off omicron fears in December, with the last month of the 2021 being the second best of the year. Ultimately, the market finished 2021 13% higher than it started. Patience pays off, unless you got in at the...

The ASX closed the second last trading day of the year – and the last full day of the year – slightly higher marking the sixth straight day of gains. This was despite a quiet day for trading and no sectors standing out with the best being t...

Highlights The ASX 200 was trading 1.6 points up at 7,511.4 in early trade. As Asia markets closed in the red on Wednesday, European stock markets closed mixed. The utilities sector is the biggest laggard today, falling 1.3%. The...

Resonance Health (RHT) receives United States Food & Drug Administration (FDA) for its new medical device LiverSmart With this FDA approval, LiverSmart will be able to be marketed and sold in the US, which is the company’s largest cust...

The Resonance Health Limited (ASX: RHT) share price is shooting the lights out on Thursday. This comes after the company announced it has received a 510(k) clearance from the US Food and Drug Administration (FDA) regarding its newest medic...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Resonance Health (RHT) submits its LiverSmart device to the FDA for US regulatory clearance LiverSmart is the company’s newest AI medical device, reviewing chest CT scans of patients with suspected pulmonary embolism The device also combin...

The ASX 200 Health Index (XHJ) is down by 0.67% at the time of writing, compared to the broader index which is up by 0.47%. Alcidion Group (ASX:ALC) rose nearly 8% this morning, after revealing that it was a member of a consortium awarded a...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Highlights The rising population and the rise in health issues are increasing the demand for healthcare products and services. People’s lifestyle is one of the reasons for rising health issues in the present times. TLX, RHT, CYC, IPD,...

The ASX 200 Health Index (XHJ) is down by 2.2% at the time of writing, compared to the broader index which is down by 0.60%. AusCann Group (ASX:AC8) is about to commence an exploratory cannabinoid (CBD) trial in people with spinal cord inju...

Wall Street mixed after previous day’s inflation-led rout US stocks closed in mixed territory on Thursday, after a selloff on Wednesday triggered by the high-inflation data release. The Dow Jones continued its slide, down by 0.34%, but the...

Perth-based medical technology company Resonance Health is gearing up to launch a new device that uses artificial intelligence to assess liver health.

Wall Street falls as IMF warns of inflation US stock markets fell for the third consecutive day, as the International Monetary Fund (IMF) cuts its global growth projection from 6.5% to 5.9%, and warned about inflation. The IMF told the BBC...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...